Aegis Capital Corp. has raised its price target on Progenics Pharmaceuticals (NASDAQ: PGNX) to $14 from $11 with expectations of an accelerated adoption ramp for the company’s Azedra. On February 14, 2017, the company announced the commencement of enrollment in an investigator initiated phase 1 clinical trial with 131-I-MIP-1095 (1095) at MSK. Progenics recently conducted a phase 2b trial of Azedra, which has demonstrated tumor reduction despite the trials primary endpoint being reduction in anti-hypertensive medication. The company previously reported that 31.7% of patients reached the primary end point.
“There is currently no alternative treatment for pheo-para, thus we believe Azedra will receive a speedy FDA review … Our new price target reflects our expectations of a faster adoption ramp for Azedra. We note that while only about 1,000 patients a year, these patients are well identified and in need of treatment, thus the ramp should be quicker than we previously modeled,” says the analyst note.
For more information visit www.progenics.com
Progenics Pharmaceuticals, Inc. develops innovative medicines and other technologies to help physicians and patients target and treat cancer. The company’s pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA® and 1095), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyLTM) intended to enable clinicians and patients to accurately visualize and assist with the management of their disease, and 3) imaging analysis tools and solutions for medical decision support. Progenics’ first commercial product, RELISTOR®(methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant Pharmaceuticals International, Inc.
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer